Arthur J. Gallagher & Co.
AJG
$268.04
-1.08%
Arthur J. Gallagher & Co. is a global insurance brokerage and risk management firm that generates the bulk of its revenue from commissions and fees earned placing property, casualty, and benefits coverage for middle-market clients, supplemented by a risk management segment providing third-party claims administration to self-insured organizations. Founded in 1927 and now employing roughly 72,000 people across a business that derives about a third of revenue internationally (notably Australia, Canada, New Zealand, and the UK), Gallagher is best characterized as a disciplined, acquisition-fueled consolidator within the highly fragmented insurance brokerage industry rather than a disruptor — its identity is built on a decentralized, roll-up model that compounds organic growth with dozens of tuck-in deals annually. The current investor narrative centers on whether that machine can sustain its historically premium multiple as organic growth decelerates toward mid-single digits, with the stock down roughly 9% over the past year against a 15.5% gain for the S&P 500 and trading well below its 52-week high despite a sharp late-October rebound. Debate also hinges on the earnings quality of recent quarters — Q2 2026 revenue grew 24.3% year-over-year to $4.0 billion, but net income fell to $323 million from $366 million a year earlier, a divergence that has kept valuation and margin durability at the center of the bull-bear argument.…
AJG
Arthur J. Gallagher & Co.
$268.04
Investment Opinion: Should I buy AJG Today?
Rating: Hold. The core thesis is that AJG is a high-quality franchise with a low beta of 0.547 and a unanimous analyst buy rating (mean 1.78), but current margin compression and acquisition-driven growth warrant caution until profitability stabilizes. The average target price of $283.33 implies 11.2% upside, but the stock is already within 4.9% of the lowest analyst target of $242.00, suggesting limited near-term upside unless earnings estimates are revised upward.
Supporting evidence includes a forward PE of 17.21x, which is a discount to the trailing PE of 44.39x and implies the market expects earnings to more than double. Revenue growth is robust at 24.3% YoY in Q2 2026, and TTM free cash flow of $2.287 billion provides a 3.4% FCF yield. However, net margin fell to 8.07% from 11.36%, and operating margin compressed to 14.69% from 19.39%, highlighting profitability concerns. The dividend yield of 0.99% is modest, and the payout ratio of 44.6% is sustainable but not a major attraction.
Key risks that could invalidate the thesis include a failure to improve margins, which would likely lead to downward EPS revisions and a lower stock price. Additionally, the wide analyst target range ($242-$388) and EPS estimate dispersion ($14.15-$18.41) indicate uncertainty. The rating would upgrade to Buy if Q3 2026 margins show sequential improvement (e.g., operating margin above 18%) and organic growth accelerates. It would downgrade to Sell if revenue growth decelerates below 15% or if forward EPS estimates are cut by more than 10%. Valuation verdict: fairly valued to slightly undervalued relative to its own history (PS of 4.83x vs. historical 11.7x-25.5x), but the discount may be warranted given current margin pressures.
Sign up to view all
AJG 12-Month Price Forecast
AJG presents a balanced risk/reward with a neutral stance. The stock's 9% one-year decline and margin compression are concerning, but the forward valuation and unanimous analyst support suggest limited downside. The key tension is whether margins can recover; if Q3 2026 shows improvement, the stock could re-rate toward the average target. Conversely, if margin pressure persists, the low target of $242 could be tested. I would upgrade to bullish if operating margin exceeds 18% and organic growth accelerates, and downgrade to bearish if revenue growth falls below 15% or EPS estimates are cut.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Arthur J. Gallagher & Co.'s 12-month outlook, with a consensus price target around $283.33 and implied upside of +5.7% versus the current price.
Average Target
$283.33
0 analysts
Implied Upside
+5.7%
vs. current price
Analyst Count
—
covering this stock
Price Range
$242 - $388
Analyst target range
Coverage is robust, with 18 analysts and a consensus recommendation of "buy" (mean rating 1.78 on a 1-5 scale where lower is more bullish), and the average target price of $283.33 implies roughly +11.2% upside from the current $254.88. The consensus leans clearly bullish — the institutional ratings feed shows a wall of reaffirmations at Overweight/Outperform/Buy from Morgan Stanley, RBC Capital, Wells Fargo, Mizuho, Argus, Citigroup, and UBS between late July and late September 2026, with no downgrades in the visible record. That unanimity is a double-edged signal: it confirms sell-side conviction in the franchise, but the absence of fresh upgrades means the bullish case is already well reflected in ratings, and the stock's 9% one-year decline despite this support suggests the market has been discounting the analysts rather than following them. The target range of $242.00 to $388.00 is wide — the high target is 52.2% above the current price and 37.0% above the average, while the low target of $242.00 sits 5.1% below the current price. The high target likely assumes successful integration of the acquisition pipeline, a rebound in margins toward the Q1 2026 level (25.6% operating margin), and multiple expansion back toward historical PS/PB norms; the low target effectively prices in continued margin compression and skepticism that the 24% revenue growth is durable or organic. The spread of $146 between low and high (60% of the average target) signals meaningful disagreement about the earnings trajectory, consistent with the trailing-versus-forward PE gap; the consensus EPS estimate of $16.66 (range $14.15-$18.41) and revenue estimate of $19.54 billion (range $18.96-$20.10 billion) show the Street expects roughly 3-4% revenue dispersion but 30% EPS dispersion, meaning the debate is about margins, not the top line. With the stock having just rallied 7.5% in two sessions to $254.88, it now sits within 4.9% of the lowest analyst target, which historically marks a zone where either the low target gets raised or the stock stalls.
Bulls vs Bears: AJG Investment Factors
The bear case currently has stronger evidence, primarily due to the clear margin compression in Q2 2026 (net margin down to 8.07% from 11.36%) despite 24% revenue growth, and the stock's 9% one-year decline against a 15.5% market gain. However, the bull case is supported by a forward PE of 17.21x that implies deep value if earnings normalize, a unanimous analyst buy rating with 11.2% upside to the average target, and a low beta of 0.547 that offers defensive characteristics. The single most important tension is whether the Q2 margin squeeze is a temporary integration cost or a structural issue—if margins recover toward Q1 2026 levels (25.6% operating margin), the stock could re-rate sharply; if not, the forward earnings estimates may be too optimistic.
Bullish
- Forward PE of 17.2x implies deep value: The trailing PE of 44.39x collapses to a forward PE of 17.21x based on consensus EPS of $16.66, a 61% compression that suggests the market is pricing a sharp earnings normalization. At the current price of $254.88, the stock trades at just 15.3x forward earnings, a discount to insurance broker peers like Marsh & McLennan and Aon that historically trade in the high-teens to low-20s.
- Revenue growth of 24.3% YoY: Q2 2026 revenue rose 24.29% to $4.003 billion from $3.221 billion, following Q1 2026 growth of 27.6% and Q4 2025 growth of 33.6%. While acquisition-driven, this top-line momentum supports the thesis that Gallagher's roll-up model continues to scale, and consensus expects $19.54 billion in revenue for the forward period.
- Analyst consensus buy with 11.2% upside: All 18 analysts rate AJG a buy (mean rating 1.78), with an average target price of $283.33, implying 11.2% upside from $254.88. The high target of $388.00 suggests 52.2% upside, and the absence of downgrades in the visible record reinforces sell-side conviction.
- Low beta of 0.547 offers defensive profile: With a beta of 0.547, AJG is roughly 45% less volatile than the market, making it an attractive defensive holding in uncertain macro environments. This low correlation to the S&P 500 (which gained 15.53% over the past year while AJG fell 9.03%) suggests stock-specific issues have driven underperformance, potentially creating a contrarian opportunity.
Bearish
- Margin compression despite revenue growth: Q2 2026 net income fell to $323 million (8.07% net margin) from $366 million (11.36% margin) a year earlier, while operating margin compressed to 14.69% from 19.39%. This divergence—24% revenue growth but lower profits—undermines the operating leverage thesis and raises questions about acquisition integration costs and SG&A discipline.
- Acquisition-driven growth may be low quality: The 24.3% revenue growth is well above organic brokerage pricing, implying acquisitions are a major contributor. This raises concerns that growth is being bought rather than earned, and the Q2 cash flow statement shows $325 million spent on acquisitions, contributing to negative free cash flow of -$41 million for the quarter.
- Relative underperformance vs. S&P 500: AJG is down 9.03% over the past year versus a 15.53% gain for SPY, a relative-strength gap of -24.56 percentage points. Despite a recent 15.01% six-month rally, the stock remains 10.4% below its 52-week high of $284.33 and has only recently regained leadership with a 3-month relative strength of -2.30.
- Wide analyst target dispersion signals uncertainty: The target range of $242.00 to $388.00 spans 60% of the average target, with the low target just 5.1% below the current price. This dispersion, combined with a 30% spread in EPS estimates ($14.15 to $18.41), indicates significant disagreement about the earnings trajectory and margin recovery.
AJG Technical Analysis
AJG is in a recovery phase within a broader one-year downtrend: the stock is down 9.03% over 12 months versus a 15.53% gain for SPY, a relative-strength gap of -24.56 percentage points, yet it has rallied 15.01% over six months and 4.55% over the past month. At $254.88, the shares sit at roughly 89.6% of the 52-week range (low $190.75, high $284.33) — near the upper end but still about 10.4% below the high, a positioning that reflects improving momentum without the overextension of a fresh breakout. The 52-week low was set during the spring drawdown (the stock traded near $192 in mid-May), and the round-trip from that level implies the market has largely repaired the damage from the earlier selloff. Recent momentum is clearly accelerating: the 1-month change of +4.55% and the 3-month change of +0.39% compare favorably to the flat-to-negative YTD reading of -0.44%, and the last two sessions alone saw a jump from $237.04 on October 14 to $250.10 and then $254.88, a +1.91% single-day move on October 16. That short-term thrust diverges sharply from the negative 1-year trend, which typically signals either the early stage of a trend reversal or a mean-reversion rally within a downtrend; the 6-month gain of 15.01% versus SPY's 7.48% (relative strength +7.53) supports the reversal interpretation, though the 3-month relative strength of -2.30 shows the stock has only recently regained leadership. Key resistance sits at the $284.33 52-week high, roughly 11.5% above the current price; a decisive break above that level would confirm a new uptrend and likely trigger momentum-driven buying, while support at the $190.75 52-week low is about 25.2% below and would represent a full retracement of the recovery. The beta of 0.547 is the critical risk-management input here — Gallagher is roughly 45% less volatile than the market, meaning the 38.16% maximum drawdown recorded over the period was an unusually severe episode for a low-beta name and suggests stock-specific (not market) drivers were at work; position sizing can therefore be larger than for a high-beta peer, but the drawdown history argues for respecting the $230-$240 area as intermediate support.
Beta
0.55
0.55x market volatility
Max Drawdown
-38.2%
Largest decline past year
52-Week Range
$191-$284
Price range past year
Annual Return
-5.1%
Cumulative gain past year
| Period | AJG Return | S&P 500 |
|---|---|---|
| 1m | +16.7% | -1.0% |
| 3m | +8.2% | +2.9% |
| 6m | +24.4% | +6.5% |
| 1y | -5.1% | +13.1% |
| ytd | +4.7% | +11.4% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
AJG Fundamental Analysis
Revenue is growing briskly but with visible lumpiness: Q2 2026 revenue of $4.003 billion rose 24.29% year-over-year from $3.221 billion in Q2 2025, following Q1 2026 revenue of $4.758 billion (up 27.6% from $3.727 billion) and Q4 2025 revenue of $3.628 billion (up 33.6% from $2.716 billion). The sequential pattern — Q1 being the seasonally largest quarter at $4.758 billion, then Q2 at $4.003 billion — is consistent with Gallagher's brokerage calendar, but the deceleration in the YoY rate from Q4's +33.6% to Q2's +24.3% bears watching. Segment disclosure shows commissions of $2.442 billion as the dominant revenue line, with the brokerage segment at $1.183 billion, contingent revenue at $91 million, investment performance at $98 million, and supplemental revenue at $141 million — meaning the commission-based core is the growth engine while contingent and investment income are smaller, more cyclical contributors. The 24% top-line growth is well above what organic brokerage pricing would deliver, implying acquisitions remain a major contributor, which raises the question of whether growth is being bought rather than earned. Profitability is the weak link in the current quarter: Q2 2026 net income of $323 million (net margin 8.07%) fell from $366 million (11.36% margin) a year earlier despite the 24% revenue increase, and operating margin compressed to 14.69% from 19.39%. Q1 2026 was far stronger — net income of $822 million on a 17.28% net margin and 25.60% operating margin — so the first half blended to a respectable but uneven result, and the Q2 compression appears driven by a $2.33 billion SG&A load plus $358 million of D&A and $168 million of interest expense. The reported gross margin of 54.75% (versus 80.91% in the Q2 income statement on a different cost classification) and operating margin of 18.28% are structurally lower than pure-software peers but consistent with a people-intensive brokerage model; the key issue is that margin is trending the wrong way even as revenue scales, which undermines the operating-leverage thesis. Balance sheet and cash flow present a mixed picture: debt-to-equity of 0.60 is moderate, the current ratio of 1.06 is thin but typical for a brokerage that holds client funds, and TTM free cash flow of $2.287 billion against a $67.4 billion market cap implies a roughly 3.4% FCF yield — solid for a financial. However, the quarterly cash flow is highly seasonal and volatile: Q2 2026 operating cash flow was just $10 million with negative free cash flow of -$41 million (after $325 million of acquisitions and $51 million of capex), versus Q1 2026 operating cash flow of $957 million and FCF of $921 million. ROE of 6.41% and ROA of 2.32% are low in absolute terms, reflecting a 3.45x equity multiplier and heavy goodwill from the acquisition program; the company funds growth through a mix of internal cash and debt, and the Q2 cash squeeze alongside $732 million of debt repayment and $170 million of buybacks shows capital allocation is active but leaves less cushion than the headline FCF suggests.
Quarterly Revenue
$4.0B
2026-06
Revenue YoY Growth
+24.3%
YoY Comparison
Gross Margin
80.9%
Latest Quarter
Free Cash Flow
$2.3B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is AJG Overvalued?
Because Gallagher is profitable (Q2 2026 net income of $323 million; TTM EPS positive), the PE ratio is the appropriate primary metric, and the dispersion between trailing and forward multiples is the story: the trailing PE of 44.39x collapses to a forward PE of 17.21x, a roughly 61% compression that implies the market expects earnings to more than double. That gap is unusually wide and reflects both depressed trailing earnings (the Q2 margin squeeze and a $0.022 TTM EPS figure that appears distorted by quarterly seasonality and one-off items) and an analyst consensus EPS estimate of $16.66 for the forward period; the market is clearly pricing a normalization of earnings rather than extrapolating the current run-rate. On the secondary metrics, the picture is less flattering: PS of 4.83x, EV/Sales of 5.09x, EV/EBITDA of 21.85x, and a price-to-cash-flow of 34.91x all sit at levels that require sustained double-digit growth and margin recovery to justify. Peer comparison is constrained by the absence of a supplied industry-average multiple in the valuation dataset, so a precise premium/discount spread cannot be computed; qualitatively, insurance brokers such as Marsh & McLennan and Aon have historically traded in the high-teens to low-20s forward PE range, which would place Gallagher's 17.21x forward multiple at a modest discount to that cohort — a discount that may be warranted given the Q2 margin compression and the 24.3% revenue growth that appears acquisition-driven rather than organic. The PEG ratio of -3.68 is not meaningful given the sign of the earnings growth input and should be disregarded. Historical context is instructive: Gallagher's own PE has ranged from about 16.9x (Q1 2026) to 111.5x (Q4 2025) and 45.5x in Q2 2026, while its PS ratio has ranged from roughly 11.7x to 25.5x over the past several years. The current PS of 4.83x and PB of 2.89x are near the low end of that multi-year band — PB was above 4.5x as recently as 2023 and PS above 20x in 2024 — which suggests the stock is priced for pessimism relative to its own history rather than optimism. The caveat is that the low PS partly reflects the much larger revenue base post-acquisition, so the multiple compression is not purely a de-rating; still, at 2.89x book versus a 3.2x-5.1x historical range, the market is assigning a below-average franchise value to a business whose forward earnings power, if the $16.66 consensus is achieved, would put the stock at a reasonable 15.3x forward earnings at the current price.
PE
44.4x
Latest Quarter
vs. Historical
Mid-Range
5-Year PE Range 17x~80x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
21.8x
Enterprise Value Multiple
Investment Risk Disclosure
Financial and operational risks center on margin durability and cash flow volatility. Q2 2026 net margin fell to 8.07% from 11.36% a year earlier, and operating margin compressed to 14.69% from 19.39%, despite 24.3% revenue growth. This suggests that acquisition integration and SG&A costs ($2.33 billion in Q2) are eroding profitability. Additionally, quarterly free cash flow is highly seasonal and volatile: Q2 2026 FCF was -$41 million versus $921 million in Q1 2026, and the company spent $325 million on acquisitions and $170 million on buybacks, leaving less cushion. With debt-to-equity at 0.60 and a current ratio of 1.06, the balance sheet is moderate but not fortress-like, and low ROE of 6.41% reflects heavy goodwill from the roll-up strategy.
Market and competitive risks include valuation compression if growth decelerates or margins fail to recover. The stock trades at a trailing PE of 44.39x and EV/EBITDA of 21.85x, which requires sustained double-digit growth and margin improvement to justify. While the forward PE of 17.21x appears reasonable, it relies on consensus EPS of $16.66, which may be optimistic given the Q2 miss. The beta of 0.547 indicates low market correlation, but the 38.16% maximum drawdown over the period was severe for a low-beta name, suggesting stock-specific risks. Competitive pressures in the fragmented insurance brokerage industry, where Gallagher competes with larger players like Marsh & McLennan and Aon, could limit pricing power and organic growth. Regulatory headwinds, such as changes in insurance regulations or commission structures, could also impact revenue.
Worst-case scenario: A continued decline in organic growth, failure to integrate acquisitions profitably, and a market rotation away from defensive financials could drive the stock toward its 52-week low of $190.75, representing a 25.2% downside from the current $254.88. The analyst low target of $242.00 is only 5.1% below the current price, but a breach could trigger further selling. If margins remain compressed and forward EPS estimates are revised down, the stock could test the $190-$200 range, a loss of 22-25%. The maximum drawdown of 38.16% over the period shows the potential severity of a stock-specific selloff, and with a short ratio of 5.64, short sellers are not heavily positioned, but a negative surprise could accelerate declines.
FAQ
The most severe risk is continued margin compression, as evidenced by Q2 2026 net margin falling to 8.07% from 11.36% and operating margin to 14.69% from 19.39%. Second, acquisition integration risk: the company spent $325 million on acquisitions in Q2 2026, and failure to realize synergies could lead to goodwill impairments and lower ROE (currently 6.41%). Third, valuation risk: the trailing PE of 44.39x and EV/EBITDA of 21.85x leave little room for error, and a downward revision to EPS estimates could trigger a de-rating. Fourth, market risk: despite a low beta of 0.547, the stock suffered a 38.16% maximum drawdown, showing vulnerability to stock-specific events. A drop to the 52-week low of $190.75 would represent a 25.2% loss.
Our 12-month forecast has three scenarios: bull case (25% probability) with a target range of $283-$388, base case (55% probability) with $242-$283, and bear case (20% probability) with $190-$242. The base case is most likely, assuming gradual margin improvement and revenue growth of 15-20%, leading the stock toward the average analyst target of $283.33. The key assumption is that Q3 2026 earnings show operating margin recovering above 16%. The bull case requires margin expansion to 18%+ and multiple expansion, while the bear case assumes persistent margin pressure and EPS cuts. The wide target range reflects uncertainty, but the risk/reward is slightly skewed to the upside given the forward PE of 17.21x.
AJG appears fairly valued to slightly undervalued relative to its own history. The trailing PE of 44.39x is elevated, but the forward PE of 17.21x is reasonable and implies the market expects earnings to more than double. The PS ratio of 4.83x and PB of 2.89x are near the low end of their multi-year ranges (PS historically 11.7x-25.5x, PB 3.2x-5.1x), suggesting the stock is priced for pessimism. However, the discount may be warranted given the Q2 margin compression and acquisition-driven growth. Compared to peers like Marsh & McLennan and Aon, which trade in the high-teens to low-20s forward PE, AJG's 17.21x is at a modest discount, reflecting its current challenges.
From a risk/reward perspective, AJG is a hold rather than a strong buy. The stock trades at $254.88, with an average analyst target of $283.33 (11.2% upside) but a low target of $242.00 (5.1% downside). The forward PE of 17.21x is attractive if earnings materialize, but Q2 2026 margin compression (net margin 8.07% vs. 11.36% a year ago) is a red flag. The low beta of 0.547 and 3.4% FCF yield make it suitable for conservative investors, but near-term upside may be limited until margin trends improve. It could be a good buy for long-term investors willing to wait for margin recovery, especially on a pullback toward $240.
AJG is more suitable for long-term investment (minimum 2-3 years) given its low beta of 0.547, stable dividend (yield 0.99%, payout ratio 44.6%), and acquisition-driven growth strategy that requires time to integrate and realize synergies. Short-term trading is less attractive due to the stock's recent volatility (38.16% max drawdown) and the binary nature of quarterly earnings, which can swing on margin results. The forward PE of 17.21x and 3.4% FCF yield provide a margin of safety for patient investors, but near-term catalysts are limited. A suggested minimum holding period is 2 years to allow for margin recovery and acquisition integration.